Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Monoamine oxidase inhibitors patient information

The skeletal muscle relaxants are contraindicated in patients with known hypersensitivity. Baclofen is contraindicated in skeletal muscle spasms caused by rheumatic disorders. Carisoprodol is contraindicated in patients with a known hypersensitivity to meprobamate. Cyclobenzaprine is contraindicated in patients with a recent myocardial infarction, cardiac conduction disorders, and hyperthyroidism, hi addition, cyclobenzaprine is contraindicated within 14 days of the administration of a monoamine oxidase inhibitor. Oral dantrolene is contraindicated in patients with active hepatic disease and muscle spasm caused by rheumatic disorders and during lactation. See Chapter 30 for information on diazepam. [Pg.191]

Accordingto the FDA-approved prescribing information for the transdermal selegiline patch, patients receiving the 6 mg/24 hour dose are not required to modify their diet. However, patients receiving the 9 or 12 mg/24 hour dose are still required to follow the dietary restrictions similar to the other monoamine oxidase inhibitors (MAOIs). [Pg.800]

Monoamine Oxidase Inhibitors (MAOIs). The MAOls work in a unique fashion by blocking the activity of an enzyme that degrades each of three key brain transmitters norepinephrine, dopamine, and serotonin. These widespread effects on several brain transmitter systems make the MAOls a potentially very effective class of medications for a variety of disorders. A few small studies have evaluated the usefulness of the MAOls in the treatment of BPD and found them moderately helpful for the impulsivity associated with this illness. Unfortunately, the requirements for strict dietary restrictions due to a risk of hypertensive crisis severely limit the usefulness of MAOls in the treatment of BPD. These restrictions are a particular concern when treating patients who have problems with impulsivity and are therefore likely to have difficulty maintaining the dietary regimen. For this reason, although they may theoretically be helpful, MAOls should only be used to treat BPD after other more easily tolerated medications have been tried and have failed. In the near future, so-called reversible MAOls that appear to avoid the need for diet restrictions may become available. If so, this will allow us to reconsider their use in the treatment of BPD. For more information regarding the use of MAOls, please refer to Chapter 3. [Pg.326]

Table 21.14. Common Information for Patients taking Monoamine Oxidase inhibitors (MAOIs) Patient Information Recommendation ... Table 21.14. Common Information for Patients taking Monoamine Oxidase inhibitors (MAOIs) Patient Information Recommendation ...
Considerable information about serotonin metabolism has been learned from the action of monoamine oxidase inhibitors. One of the first of these compounds to be discovered was l-isonicotinyl-2-isopropyl hydrazide (Marsilid) 376) Many other compounds have since been discovered that inhibit monoamine oxidase both in vHxo and in vivo 368). The outcome of the studies with monoamine oxidase inhibitors has been to show that when the enzyme is inhibited there is a diminished formation of 5-hydroxyindoleacetic acid and serotonin is converted to the 0-glucuronide and excreted in rodents. In man there is little formation of serotonin glucuro-nide. The fate of serotonin in man under these conditions is not known definitely, although serotonin-O-sulfate has been observed in carcinoid patients. Serotonin may also be methylated to yield W-methyl-serotonin 368). [Pg.160]

The involvement of dopaminergic neurotransmission in AD has led to the use of agonists such as bromocriptine, lisuride, and pergolide, with poor results. A selective monoamine oxidase B inhibitor (MAO-B) such as deprenyl has also been employed. Little solid information exists on the effects of deprenyl on AD. Unfortunately, all information available comes from small studies. In a double-blind study, Tariot et al. (1987) observed that, with a daily dose of 10 mg in 17 patients with AD, a significant reduction in the scores for anxiety, depression, tension, and excitement was achieved. Burke et al. (1993), in a study of more than 20 patients with AD during a period of 15 months, found no behavioral changes in the progression of the illness nor in its scores. [Pg.503]


See other pages where Monoamine oxidase inhibitors patient information is mentioned: [Pg.7]    [Pg.8]    [Pg.83]    [Pg.229]    [Pg.83]    [Pg.36]    [Pg.17]   
See also in sourсe #XX -- [ Pg.590 ]




SEARCH



Monoamine inhibitors

Monoamine oxidase

Monoamine oxidase inhibitors

Oxidase inhibitors

Oxidases monoamine oxidase

© 2024 chempedia.info